JP2009513150A - シグナリングアッセイ及び株化細胞 - Google Patents
シグナリングアッセイ及び株化細胞 Download PDFInfo
- Publication number
- JP2009513150A JP2009513150A JP2008538163A JP2008538163A JP2009513150A JP 2009513150 A JP2009513150 A JP 2009513150A JP 2008538163 A JP2008538163 A JP 2008538163A JP 2008538163 A JP2008538163 A JP 2008538163A JP 2009513150 A JP2009513150 A JP 2009513150A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- agent
- protein
- localization
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003556 assay Methods 0.000 title abstract description 42
- 230000011664 signaling Effects 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 251
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 69
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 69
- 230000004913 activation Effects 0.000 claims abstract description 49
- 102000043136 MAP kinase family Human genes 0.000 claims abstract description 39
- 108091054455 MAP kinase family Proteins 0.000 claims abstract description 39
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 17
- 108010029485 Protein Isoforms Proteins 0.000 claims abstract description 12
- 102000001708 Protein Isoforms Human genes 0.000 claims abstract description 12
- 239000013603 viral vector Substances 0.000 claims abstract description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 76
- 102000037865 fusion proteins Human genes 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 46
- 230000004807 localization Effects 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 37
- 108700012928 MAPK14 Proteins 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000012190 activator Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 239000005090 green fluorescent protein Substances 0.000 claims description 14
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 13
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 13
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 229910052876 emerald Inorganic materials 0.000 claims description 10
- 239000010976 emerald Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 7
- 108091006047 fluorescent proteins Proteins 0.000 claims description 7
- 102000034287 fluorescent proteins Human genes 0.000 claims description 7
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 6
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 claims description 6
- 108090000848 Ubiquitin Proteins 0.000 claims description 6
- 102000044159 Ubiquitin Human genes 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 6
- 241000579895 Chlorostilbon Species 0.000 claims description 5
- 101150003941 Mapk14 gene Proteins 0.000 claims description 5
- 229940000406 drug candidate Drugs 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 4
- 108010082025 cyan fluorescent protein Proteins 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 108010054624 red fluorescent protein Proteins 0.000 claims description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 4
- 101100457336 Homo sapiens MAPK12 gene Proteins 0.000 claims description 3
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims description 3
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 claims description 3
- 101150003567 Mapk12 gene Proteins 0.000 claims description 3
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 3
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 claims description 3
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 claims description 3
- 101150105578 SAPK3 gene Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 102000047217 human NR4A3 Human genes 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000271566 Aves Species 0.000 claims description 2
- 241000701822 Bovine papillomavirus Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000701447 unidentified baculovirus Species 0.000 claims description 2
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 claims 4
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 claims 4
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 abstract description 10
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 abstract description 9
- 230000037361 pathway Effects 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 210000001822 immobilized cell Anatomy 0.000 abstract description 4
- 230000005540 biological transmission Effects 0.000 abstract description 3
- 238000001890 transfection Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 42
- 230000004044 response Effects 0.000 description 33
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 29
- 230000010473 stable expression Effects 0.000 description 24
- 210000004940 nucleus Anatomy 0.000 description 20
- 210000000805 cytoplasm Anatomy 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 14
- 230000001747 exhibiting effect Effects 0.000 description 13
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 11
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000005945 translocation Effects 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000053187 Glucuronidase Human genes 0.000 description 4
- 108010060309 Glucuronidase Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 102000004459 Nitroreductase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 108020001162 nitroreductase Proteins 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 238000012731 temporal analysis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 102000002667 Glycine hydroxymethyltransferase Human genes 0.000 description 3
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 102000039106 EBP family Human genes 0.000 description 1
- 108091065819 EBP family Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 101001048716 Homo sapiens ETS domain-containing protein Elk-4 Proteins 0.000 description 1
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 description 1
- 101001092930 Homo sapiens Prosaposin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101000822645 Oryza sativa subsp. japonica Serine/threonine-protein kinase SAPK3 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710092482 Protein kinase 4 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000242743 Renilla reniformis Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100022483 Sodium channel and clathrin linker 1 Human genes 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000010198 maturation time Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73136405P | 2005-10-28 | 2005-10-28 | |
| PCT/US2006/060251 WO2007094867A2 (en) | 2005-10-28 | 2006-10-26 | Cell-based p38 mapk translocation assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009513150A true JP2009513150A (ja) | 2009-04-02 |
| JP2009513150A5 JP2009513150A5 (https=) | 2009-11-12 |
Family
ID=38371953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538163A Pending JP2009513150A (ja) | 2005-10-28 | 2006-10-26 | シグナリングアッセイ及び株化細胞 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080227131A1 (https=) |
| EP (1) | EP1941044A2 (https=) |
| JP (1) | JP2009513150A (https=) |
| WO (1) | WO2007094867A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015019637A (ja) * | 2013-07-22 | 2015-02-02 | オリンパス株式会社 | サバイビンについての細胞解析方法、並びにそれを利用した癌の解析方法および薬効のスクリーニング方法 |
| JP2019510754A (ja) * | 2016-03-01 | 2019-04-18 | マックォーリー・ユニバーシティ | 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190381500A1 (en) * | 2018-06-14 | 2019-12-19 | Daisuke Takagi | Cell contained container and cell contained container producing method, and cell chip |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001522454A (ja) * | 1997-04-07 | 2001-11-13 | バイオイメージ エイ／エス | 細胞応答への影響に関する定量情報の抽出方法 |
| US20050118663A1 (en) * | 2003-07-30 | 2005-06-02 | Irm Llc | Methods and compositions for modulating cell proliferation |
-
2006
- 2006-10-26 WO PCT/US2006/060251 patent/WO2007094867A2/en not_active Ceased
- 2006-10-26 EP EP06850071A patent/EP1941044A2/en not_active Withdrawn
- 2006-10-26 JP JP2008538163A patent/JP2009513150A/ja active Pending
- 2006-10-26 US US12/091,579 patent/US20080227131A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001522454A (ja) * | 1997-04-07 | 2001-11-13 | バイオイメージ エイ／エス | 細胞応答への影響に関する定量情報の抽出方法 |
| US20050118663A1 (en) * | 2003-07-30 | 2005-06-02 | Irm Llc | Methods and compositions for modulating cell proliferation |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015019637A (ja) * | 2013-07-22 | 2015-02-02 | オリンパス株式会社 | サバイビンについての細胞解析方法、並びにそれを利用した癌の解析方法および薬効のスクリーニング方法 |
| JP2019510754A (ja) * | 2016-03-01 | 2019-04-18 | マックォーリー・ユニバーシティ | 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用 |
| JP7040774B2 (ja) | 2016-03-01 | 2022-03-23 | マックォーリー・ユニバーシティ | 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用 |
| JP2022078192A (ja) * | 2016-03-01 | 2022-05-24 | マックォーリー・ユニバーシティ | 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用 |
| JP7496627B2 (ja) | 2016-03-01 | 2024-06-07 | マックォーリー・ユニバーシティ | 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007094867A2 (en) | 2007-08-23 |
| WO2007094867A3 (en) | 2008-01-17 |
| EP1941044A2 (en) | 2008-07-09 |
| US20080227131A1 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI102618B (fi) | Menetelmä proteiini-inhibiittorien ja -aktivaattorien seulomiseksi | |
| Hsiao et al. | Tankyrase 2 poly (ADP-ribose) polymerase domain-deleted mice exhibit growth defects but have normal telomere length and capping | |
| JPWO2013084950A1 (ja) | タンパク質間相互作用の検出方法 | |
| Giudici et al. | A novel neuronal-specific splice variant of Type I phosphatidylinositol 4-phosphate 5-kinase isoform gamma | |
| Kishi et al. | Stable transfectants of smooth muscle cell line lacking the expression of myosin light chain kinase and their characterization with respect to the actomyosin system | |
| JP2003501074A (ja) | 概日リズムタンパク質の変化に関するスクリーニング方法 | |
| US20070259343A1 (en) | Somatic transfer of modified genes to predict drug effects | |
| US20140378324A1 (en) | Raf dimers and uses thereof | |
| JP2019037197A (ja) | ロースト様香料素材のスクリーニング方法 | |
| JP2005501548A5 (https=) | ||
| Colombo et al. | Fast detection of PKA activity in Saccharomyces cerevisiae cell population using AKAR fluorescence resonance energy transfer probes | |
| JP2009513150A (ja) | シグナリングアッセイ及び株化細胞 | |
| Mubiru et al. | A Variant of the alpha‐methyl‐acyl‐CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer | |
| Kanda et al. | Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn | |
| JP2019010058A (ja) | フェノリック香料素材のスクリーニング方法 | |
| US20080166711A1 (en) | Assays for TERT promoter modulatory agents | |
| US7662626B2 (en) | Cells and methods for estimation of effects on neurological dysfunction | |
| JP2014161321A (ja) | 発光量を補正する方法 | |
| EP1171628A2 (en) | Compound screening methods | |
| CN101200707B (zh) | 一种用于筛选抗糖尿病药物的细胞模型 | |
| US20250207173A1 (en) | Reporter cell for assessing ddx3 helicase activity | |
| JP5284479B2 (ja) | アリルハイドロカーボンレセプター転写活性化量を測定するための細胞、方法およびアッセイキット | |
| US20040146903A1 (en) | Methods and compositions for modulating activator protein 1 | |
| US7713713B2 (en) | Polypeptide having intracellular calcium ion indicator function | |
| JP4635196B2 (ja) | 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090925 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090925 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090925 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120612 |